Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 9/20 | 0.77 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.48 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | TTR | P02766 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | TYR | P14679 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3184350 | 1.00 | HDAC1 (0.77) | HDAC1ESR2NR1H2TTRAPP | |
| SCHEMBL3178393 | 0.91 | HDAC1 (0.64) | HDAC1ESR2NR1H2TTRAPP | |
| SCHEMBL3185199 | 0.91 | HDAC1 (0.64) | HDAC1ESR2NR1H2TTRAPP | |
| SCHEMBL20367229 | 0.91 | HDAC1 (0.64) | HDAC1ESR2NR1H2TTRAPP | |
| SCHEMBL3177427 | 0.89 | HDAC1 (0.62) | HDAC1ESR2NR1H2TTRAPP | |
| SCHEMBL3177432 | 0.89 | HDAC1 (0.62) | HDAC1ESR2NR1H2TTRAPP | |
| SCHEMBL3176087 | 0.87 | HDAC1 (1.00) | HDAC1 | |
| SCHEMBL3176077 | 0.87 | HDAC1 (1.00) | HDAC1 | |
| SCHEMBL13531789 | 0.86 | HDAC1 (0.67) | HDAC1ESR2NR1H2TTRAPP | |
| SCHEMBL3178100 | 0.86 | HDAC1 (0.57) | HDAC1ESR2NR1H2TTRAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100022514-A1 | Heterocycle Compounds and Methods of Use Thereof | NORVARTIS AG | 2010-01-28 | — | — | US | disclosed |
| EP-2120910-A2 | HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF | Novartis Ag (CH) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008076954-A2 | HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF | NOVARTIS AG (CH) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022514-A1 | Heterocycle Compounds and Methods of Use Thereof | HDAC1, HDAC3, HDAC10 | HDAC1 1/4885ESR2 2057/4885NR1H2 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.